Security Snapshot

UTAH MEDICAL PRODUCTS INC - Common Stock (UTMD) Institutional Ownership

CUSIP: 917488108

13F Institutional Holders and Ownership History from Q1 2014 to Q1 2026

Latest Period

Q4 2025

Institutions Reporting

116

Shares (Excl. Options)

2,099,458

Price

$55.96

Save this security page for your next review

Keep this CUSIP in your watchlists so you can revisit quarter changes from one place.

Create free account to save this page Review latest holder period
Type / Class
Equity / Common Stock
Symbol
UTMD on Nasdaq
Shares outstanding
3,203,885
Price per share
$61.99
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
2,099,458
Total reported value
$117,520,642
% of total 13F portfolios
0%
Share change
-66,340
Value change
-$3,858,775
Number of holders
116
Price from insider filings
$61.99
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Quick Takeaways

  • UTMD - UTAH MEDICAL PRODUCTS INC - Common Stock is tracked under CUSIP 917488108.
  • 116 institutions reported positions in Q4 2025.
  • 5 significant owners is listed from Schedule 13D/13G reporting.

What Changed

  • Holder count moved from 116 to 23 between Q4 2025 and Q1 2026.
  • Reported value moved from $117,520,642 to $3,359,956.

Why This Matters

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Source Evidence

Source: SEC Form 13F

Latest holder context comes from 116 institutions filings for Q4 2025.

Open SEC Evidence

Investment Quick Answers

What is CUSIP 917488108?
CUSIP 917488108 identifies UTMD - UTAH MEDICAL PRODUCTS INC - Common Stock in SEC 13F datasets.

Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.

Significant Owners of UTAH MEDICAL PRODUCTS INC - Common Stock (UTMD) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
BRANDES INVESTMENT PARTNERS, LP 10% +25% $18,559,463 +$3,434,852 333,204 +23% BRANDES INVESTMENT PARTNERS, LP 31 Aug 2025
RENAISSANCE TECHNOLOGIES LLC 6.7% $12,107,235 230,614 Renaissance Technologies LLC 30 Sep 2024
DIMENSIONAL FUND ADVISORS LP 6.1% $11,239,863 197,466 Dimensional Fund Advisors LP 30 Jun 2025
BlackRock, Inc. 5.3% +6.6% $9,829,260 +$231,666 172,684 +2.4% BlackRock, Inc. 30 Jun 2025
FMR LLC 2.7% $4,848,900 92,360 FMR LLC 31 Dec 2024

As of 31 Dec 2025, 116 institutional investors reported holding 2,099,458 shares of UTAH MEDICAL PRODUCTS INC - Common Stock (UTMD). This represents 66% of the company’s total 3,203,885 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of UTAH MEDICAL PRODUCTS INC - Common Stock (UTMD) together control 58% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
BRANDES INVESTMENT PARTNERS, LP 11% 351,322 +4% 0.15% $19,659,979
DIMENSIONAL FUND ADVISORS LP 6.1% 196,509 -1.8% 0% $10,996,729
RENAISSANCE TECHNOLOGIES LLC 6% 193,614 -3.6% 0.02% $10,834,639
BlackRock, Inc. 5.8% 184,537 +2.6% 0% $10,326,685
VANGUARD GROUP INC 5.5% 175,971 +0.2% 0% $9,847,338
HOTCHKIS & WILEY CAPITAL MANAGEMENT LLC 3.4% 109,001 0% 0.02% $6,099,696
Minerva Advisors LLC 2.9% 93,615 +0.6% 3.5% $5,238,695
GEODE CAPITAL MANAGEMENT, LLC 2.7% 87,795 -2.4% 0% $4,914,217
STATE STREET CORP 2.1% 68,007 -3.2% 0% $3,826,574
RICE HALL JAMES & ASSOCIATES, LLC 2% 64,398 +4.8% 0.2% $3,603,712
MORGAN STANLEY 1.4% 43,705 -24% 0% $2,445,771
Huber Capital Management LLC 1.1% 36,840 -23% 0.3% $2,061,566
Bank of New York Mellon Corp 1.1% 35,539 -22% 0% $1,988,789
NORTHERN TRUST CORP 0.91% 29,277 -6.8% 0% $1,638,341
Cardinal Capital Management 0.78% 24,836 +1.9% 0.18% $1,394,243
Quantinno Capital Management LP 0.74% 23,695 +3.2% 0% $1,325,996
EVERETT HARRIS & CO /CA/ 0.67% 21,344 +24% 0.01% $1,194,410
BARD ASSOCIATES INC 0.57% 18,200 -12% 0.26% $1,024,677
MILLENNIUM MANAGEMENT LLC 0.51% 16,348 -20% 0% $914,834
Qube Research & Technologies Ltd 0.48% 15,274 +13% 0% $854,733
O'SHAUGHNESSY ASSET MANAGEMENT, LLC 0.47% 14,903 +2.3% 0% $833,972
PRICE T ROWE ASSOCIATES INC /MD/ 0.46% 14,680 -9.2% 0% $823,000
LSV ASSET MANAGEMENT 0.42% 13,474 +3.9% 0% $754,000
AMERIPRISE FINANCIAL INC 0.42% 13,400 0% 0% $749,864
FMR LLC 0.41% 13,240 +3.7% 0% $740,889

Institutional Holders of UTAH MEDICAL PRODUCTS INC - Common Stock (UTMD) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q1 54,084 $3,359,956 +$149,790 $61.99 23
2025 Q4 2,099,458 $117,520,642 -$3,858,775 $55.96 116
2025 Q3 2,166,272 $136,441,085 +$654,850 $62.97 115
2025 Q2 2,154,610 $122,645,130 -$4,286,491 $56.92 109
2025 Q1 2,232,321 $125,139,291 -$4,053,654 $56.04 107
2024 Q4 2,305,146 $141,733,881 -$6,984,040 $61.47 112
2024 Q3 2,408,468 $161,160,273 +$1,503,694 $66.91 109
2024 Q2 2,402,050 $160,517,663 -$6,987,298 $66.81 99
2024 Q1 2,489,842 $177,079,892 -$5,994,623 $71.11 99
2023 Q4 2,515,087 $211,858,896 -$5,241,769 $84.22 88
2023 Q3 2,572,783 $221,288,021 +$1,886,299 $86.00 91
2023 Q2 2,546,722 $237,462,990 +$487,123 $93.20 89
2023 Q1 2,542,875 $241,013,763 +$8,482,645 $94.77 86
2022 Q4 2,546,245 $255,980,665 +$1,190,438 $100.53 81
2022 Q3 2,535,532 $216,324,656 -$31,278,340 $85.31 75
2022 Q2 2,559,522 $219,885,103 -$450,030 $85.90 74
2022 Q1 2,572,731 $231,180,696 -$2,805,351 $89.86 84
2021 Q4 2,603,370 $260,419,500 -$912,880 $100.00 78
2021 Q3 2,601,860 $241,516,691 +$243,574 $92.83 72
2021 Q2 2,599,575 $221,087,106 -$2,811,784 $85.04 68
2021 Q1 2,632,036 $227,952,680 +$1,009,922 $86.60 78
2020 Q4 2,620,725 $220,943,842 -$2,326,872 $84.30 76
2020 Q3 2,651,007 $211,813,071 -$2,768,168 $79.87 83
2020 Q2 2,681,470 $237,657,730 +$3,950,332 $88.62 91
2020 Q1 2,628,004 $247,165,094 -$14,110,945 $94.05 89
2019 Q4 2,771,884 $299,105,893 -$7,842,685 $107.90 95
2019 Q3 2,845,261 $272,705,817 +$14,362,424 $95.84 94
2019 Q2 2,695,866 $257,857,946 +$3,901,787 $95.70 96
2019 Q1 2,667,666 $235,422,594 -$153,905 $88.25 90
2018 Q4 2,678,889 $222,557,936 -$9,708,244 $83.08 85
2018 Q3 2,788,384 $262,649,786 +$18,705,556 $94.20 89
2018 Q2 2,586,431 $284,806,927 +$1,054,670 $110.15 91
2018 Q1 2,585,740 $255,600,294 +$9,117,799 $98.85 78
2017 Q4 2,497,435 $203,092,527 +$2,126,789 $81.40 78
2017 Q3 2,480,589 $182,487,296 +$233,743 $73.55 74
2017 Q2 2,477,645 $179,356,830 +$4,870,819 $72.40 75
2017 Q1 2,421,128 $150,830,508 +$6,332,169 $62.30 76
2016 Q4 2,477,886 $180,211,111 -$462,985 $72.75 75
2016 Q3 2,500,148 $149,501,799 -$1,271,482 $59.80 78
2016 Q2 2,519,897 $158,750,245 -$2,050,779 $63.00 76
2016 Q1 2,555,094 $159,803,564 +$3,079,935 $62.54 68
2015 Q4 2,531,311 $148,131,615 +$2,531,634 $58.54 65
2015 Q3 2,466,259 $133,025,937 -$477,134 $53.87 58
2015 Q2 2,473,912 $147,468,790 +$3,581,938 $59.63 63
2015 Q1 2,413,527 $144,447,777 -$3,605,115 $59.86 59
2014 Q4 2,473,676 $148,510,172 -$16,219 $60.05 60
2014 Q3 2,205,551 $107,547,653 -$11,678,366 $48.76 60
2014 Q2 2,427,382 $124,860,931 +$1,473,685 $51.44 60
2014 Q1 2,397,038 $138,529,175 +$3,536,633 $57.83 58
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Here you can make detailed settings or revoke your consent (in part if necessary) with effect for the future. For further information, please refer to our Privacy Policy .